PTGX.US Protagonist Therapeutics Inc

Healthcare Biotechnology USA Stocks
123.37 USD
Close of Nov 17, 2026
77.00 160.81
Market cap
USD 8.05B
P/E
26.1x
P/B
7.87x
ROE
47.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PTGX.US undervalued?

Graham number

The Graham number of Protagonist Therapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Protagonist Therapeutics Inc fundamental analysis

No fundamental analysis for Protagonist Therapeutics Inc yet.

Protagonist Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia ve…

Full company profile